Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
| Autor: | Eero Pekkonen, Egon Kurča, P. Vanni, Eric Freire-Alvarez, Luigi M Barbato, Cleanthe Spanaki, Yang Liu, Olga Sanchez-Soliño, Lydia Lopez Manzanares |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Parkinson's disease Movement disorders law.invention Antiparkinson Agents Levodopa 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Quality of life Rating scale law Internal medicine Activities of Daily Living medicine Humans Adverse effect 030304 developmental biology 0303 health sciences Dyskinesias business.industry Carbidopa Parkinson Disease medicine.disease 3. Good health Drug Combinations Neurology Dyskinesia Quality of Life Levodopa carbidopa Neurology (clinical) medicine.symptom business Gels 030217 neurology & neurosurgery |
| Zdroj: | Movement Disorders. 36:2615-2623 |
| ISSN: | 1531-8257 0885-3185 |
| DOI: | 10.1002/mds.28703 |
| Popis: | BACKGROUND There are limited data regarding the effectiveness of levodopa-carbidopa intestinal gel (LCIG) for dyskinesia. OBJECTIVE Compare the effectiveness of LCIG versus oral optimized medical treatment (OMT) for dyskinesia in patients with advanced Parkinson's disease (PD) using the Unified Dyskinesia Rating Scale (UDysRS). METHODS This phase 3b, open-label, multicenter, 12-week, interventional study (NCT02799381) randomized 63 LCIG naive patients with advanced PD (UDysRS ≥30) to LCIG (N = 30) or OMT (N = 33) treatment. Dyskinesia impact was assessed at baseline through week 12 using the UDysRS. PD-related motor and non-motor symptoms, and quality of life (QoL) were also assessed. RESULTS Dyskinesias measured by UDysRS were significantly reduced in the LCIG group (n = 24; -17.37 ± 2.79) compared with the OMT group (n = 26; -2.33 ± 2.56) after 12 weeks (-15.05 ± 3.20; 95% CI, -21.47 to -8.63; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text